Related Experiment Videos
Low molecular weight heparin in children
Manuela Albisetti1, Maureen Andrew
1Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. manuela.albisetti@kispi.unizh.ch
European Journal of Pediatrics
|April 17, 2002
Summary
Low molecular weight heparins offer a safe and effective alternative for preventing and treating blood clots in children. These agents provide predictable anticoagulation with fewer complications than traditional treatments.
Area of Science:
- Pediatric Hematology
- Pharmacology
Background:
- Thromboembolic events pose risks in pediatric patients.
- Current anticoagulation options include unfractionated heparin and oral anticoagulants.
Purpose of the Study:
- To evaluate the efficacy and safety of low molecular weight heparins (LMWHs) in pediatric thromboembolism.
- To compare LMWHs with unfractionated heparin and oral anticoagulants in children.
Main Methods:
- Review of available data on LMWH use in pediatric populations.
- Analysis of pharmacokinetic and pharmacodynamic properties of LMWHs versus unfractionated heparin.
Main Results:
- LMWHs demonstrate superior bioavailability and longer half-life compared to unfractionated heparin.
- Subcutaneous administration of LMWHs requires minimal monitoring and dose adjustment.
- Complications like osteoporosis and heparin-induced thrombocytopenia are less frequent with LMWHs.
Conclusions:
- Low molecular weight heparins represent an efficient and safe alternative for anticoagulation in children.
- LMWHs are suitable for both prevention and treatment of thromboembolic events across various pediatric conditions.